Skip to main content
. 2012 Jan 24;302(7):E841–E851. doi: 10.1152/ajpendo.00599.2011

Fig. 1.

Fig. 1.

Serum and urine biochemistry. Serum hPTH(1–34) (A), calcium (B), phosphorus (C), 1,25(OH)2D (D), and urine calcium/creatinine ratio (E) in 12-wk-old WT, Pth−/−, and Pth−/−-Casr −/− mice infused with 60 μg·kg−1·day−1 hPTH(1–34) or vehicle for 2 wk. Each value is the mean ± SE (n = 8/genotype). Symbols indicate significant changes, using 1-way ANOVA as described in Statistical analysis. *P < 0.05 and **P < 0.01 compared with vehicle-infused mice of the corresponding genotype. +P < 0.05 compared with vehicle-infused WT mice. WT, wild type; hPTH, human PTH; Casr, calcium-sensing receptor. Results of 2-way ANOVA using genotype (Pth−/− and Pth−/−-Casr−/−) and parathyroid hormone (PTH) infusion treatment (vehicle and PTH infusion) as main effects: serum hPTH(1–34): genotype, P = 0.573; PTH, P < 0.001; genotype × PTH, P = 0.573. Serum calcium: genotype, P = 0.583; PTH, P < 0.01; genotype × PTH, P = 0.466. Serum phosphorus: genotype, P = 0.952; PTH, P < 0.001; genotype × PTH, P = 0.435. Serum 1,25(OH)2D3: genotype, P = 0.977; PTH, P < 0.001; genotype × PTH, P = 0.792. Urine calcium/creatine: genotype, P = 0.027: PTH, P = 0.442; genotype × PTH, P = 0.107.